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atic patients with 60% stenosis or more who were treated
medically had a 5-year aggregate risk for any perioperative
stroke or death and ipsilateral stroke of 11%.2
A high-risk patient population may be initially eval-
uated as part of a multicenter nonrandomized trial that
uses historical control data for comparison of results.
The sample size for such a trial would be derived from (1)
the anticipated risk of the study population for ipsilateral
stroke and perioperative stroke and death and (2) the risk
of the comparison population for the same end points.
When all patients with medical comorbidities are consid-
ered (Appendix Tables II-IV), it becomes apparent that
their CEA complication rates are predominantly in the
range of 10% to 20%. Because these rates were observed
at 30 days or less after surgery, the 1-year complication
rate is expected to be 1% to 2% higher, on the basis of
data from the NASCET study. Thus, it seems reasonable
to propose a historical control of 15% for the composite
end point of stroke, death, and MI at 30 days and
ipsilateral stroke at 1 year for this subset of patients.
Similarly, the group of patients with anatomic conditions
would be expected to have risks similar to those of
patients treated medically. On the basis of data from the
NASCET and ACAS trials, a proposed reasonable histor-
ical control for this set of patients is 11%.
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The ARCHeR trial represents an important contribution that
provides data regarding the safety and efficacy of the Guidant
Acculink and Accunet carotid stent and filter systems and also adds
to the growing data pool on the results of carotid stenting in
high-risk patients.
It is important, however, that the limitations of this study be
fully understood. The ARCHeR trial is not a prospective, random-
ized, controlled trial. It is not a comparative trial at all. It is an
industry-sponsored, multi-institutional case registry. This registry
was developed in order to accumulate a body of data on the
performance of the Guidant products with a major goal of gaining
Food andDrug Administration approval. It must be noted that the
majority of the coauthors of this paper are either Guidant employ-
ees or consultants or receive financial support from Guidant.
In order to garner Food and Drug Administration approval,
the authors needed to show that the results of treatment with their
product were not inferior to the results of standard treatment
(carotid endarterectomy; CEA). As a basis for comparison, they
used historical controls derived from selected series in the litera-
ture. By methods that are difficult to understand, they arrived at a
control group (CEA) composite adverse event rate of 14.4%, to
which they compare their stenting results (composite adverse event
rate of 9.6%). Bias in selection of the series used to determine their
control group adverse event rate is evident. The control group even
included series of patients undergoing simultaneous coronary ar-
tery bypass grafting and CEA, a group in which stroke and mor-
tality rates are high and in which the majority of strokes and deaths
are not CEA related. In their appendix, the authors cite many series
to support their control group adverse event rate, but they omit
several series as well. For example, in 2003, Gasparis et al1 reported
on 228 high-risk CEA patients.1 Their definition of high risk
was at least as stringent as that used by the ARCHeR team (age
80 years, myocardial infarction in the prior 6 months, New York
Heart Association class III or IV angina, Canadian Heart Associa-
tion (CHA) class III or IV congestive heart failure, steroid- or
oxygen-dependent chronic obstructive pulmonary disease, creati-
nine of 3 mg/dl or greater, contralateral occlusion, carotid reop-
eration, prior neck irradiation, or high lesion). The 30-day results
of CEA in these patients included mortality, myocardial infarction,
and stroke rates of 0.4%, 0.9%, and 0.9%, respectively, with a
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combined stroke/death rate of 1.3%. There are other reports of
CEA in high-risk patients that call into question the validity of the
ARCHeR authors’ control group adverse event rate.2,3
Even if the reader discounts the comparative data in this article,
the results are interesting. In symptomatic patients, the 30-day stroke,
death, and combined stroke/death rates were 10.9%, 2.2%, and
11.6%, respectively. In asymptomatic patients, the rates were 3.8%,
2.0%, and 5.4%. It should be noted that just as in the CEA trials,
the results achieved in ARCHeR by experienced carotid interven-
tionalists in large programs may not be reflective of the results
likely to be achieved by less highly selected or experienced inter-
ventionalists.
The data on durability are also notable. Although the target
lesion revascularization rate at 1 year was only 2.2%, fully 26% of
patients had 50% to 69% restenosis, and 5% had more than 70%
restenosis at 1 year. In the relatively small number of patients
followed up for 2 and 3 years, the incidence of 50% to 69% and
greater than 70% restenosis did not increase.
While the ARCHeR trial contains a wealth of data on the
results of carotid stenting with the Guidant products, it does not
provide a valid assessment of the relative merits of stenting and
CEA in the management of high-risk patients. Definitive assess-
ment of the relative merits of stenting and CEA awaits properly
designed and conducted prospective randomized controlled trials.
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